Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 02 Mar 2023
Patients with type 2 diabetes who used a smartphone app for cognitive behavioral therapy showed a significant decrease in A1c levels.
Read Full Newsargenx's efgartigimod-alfa therapy was approved for seropositive generalized myasthenia gravis in 2021.
Early initiation of opicapone significantly reduces OFF time and enhances ON time in patients with recently diagnosed Parkinson's disease, improving overall treatment outcomes.
The FDA requested the full data from the phase 3 HOPE-3 study as part of its review of the biologics license application for deramiocel, which Capricor plans to submit in February 2026.
A five-year analysis from the National RLS Opioid Registry found that most patients with dopamine agonist augmented restless legs syndrome maintained stable, low-dose opioid therapy with sustained symptom control.
Personalized Care Improvements Identified for Older Patients with Skin Cancer
New Findings on Acne Incidence in Transgender Individuals, With Howa Yeung, MD, MSc
What to Expect at the 2026 Maui Derm Conference
1.
FDA Expands Durvalumab Label to Operable Lung Cancer
2.
Fear of hair loss might cause some to reject cancer treatment
3.
Discovery of breast cancer treatment resistance mechanism could lead to new hope for some
4.
Study opens up possibility of bespoke prostate cancer treatment
5.
FAPI PET/CT enhances the staging of recently discovered breast cancer, according to comparative analysis.
1.
Navigating the Evolving Landscape of Oncology Clinical Trials in the Era of Precision Medicine
2.
Vaso Occlusive Crisis: Understanding the Painful Reality of Sickle Cell Disease
3.
Hematologic Toxicity of CDK4/6 Inhibitors in Breast Cancer: Meta-Analysis and Safety Data
4.
Understanding Extramammary Paget's Disease: Causes, Symptoms and Treatment Options
5.
Thyroid Cancer and Insulin Resistance: Unraveling the Complex Interplay for Better Patient Outcomes
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Efficient Management of First line ALK-rearranged NSCLC
2.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases - Part II
3.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part IV
4.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion III
5.
Experts' Opinion on the Goal of Treatment of Patients with Relapsed Adult B-cell ALL
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge